Long-term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexate.
Stine
Kimo C
KC
Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Arkansas 72202, USA. stinekimoc@uams.edu
Saylors
Robert L
RL
Saccente
Suzanne
S
Becton
David L
DL
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy*; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D006811:Humerus; D007223:Infant; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D016609:Neoplasms, Second Primary / Q000150:complications / Q000188:drug therapy*; D012516:Osteosarcoma / Q000150:complications / Q000188:drug therapy*; D019572:Retinal Neoplasms / Q000150:complications* / Q000473:pathology; D012175:Retinoblastoma / Q000150:complications* / Q000473:pathology; D017741:Survivors; D013977:Tibia
D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate